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INTRODUCTION
Atopic dermatitis (AD) is a common chronic inflammatory 
skin disease affecting 15-25% of children and 3% among adults.
1-3 
It is strongly associated with asthma and allergic sensitization.
1-3 
Recent data showed that AD is a major problem in developing, 
as well as developed countries.
1 Approximately 85% of patients 
with AD begin during early childhood, and 70% of patients se-
vere AD develop asthma or allergic rhinitis later in life.
4-6 Patients 
with severe or persistent AD and their families suffer from sig-
nificant impairment in their quality of life.
7 In addition, AD 
places a heavy economic burden not only on patients and their 
families, but also on society in general.
8,9 AD skin is character-
ized by immune dysregulation and epidermal barrier defects 
such as abnormal terminal differentiation of keratinocytes and 
decreased cornification.
6,10-12 This review will focus on structur-
al abnormalities in the epidermis and their modulation by im-
mune responses. 
Normal epidermal barrier
The epidermis provides a physical and permeability barrier 
(Figure).
13-15 This barrier is continuously regenerated by termi-
nally differentiating keratinocytes, a process known as cornifi-
cation or keratinization. Epidermal differentiation begins with 
the migration of keratinocytes from the basal layer, and ends 
with the formation of the cornified layer.
13,14 Human epidermis 
undergoes complete turnover every 28 days.
16 Cell prolifera-
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tion, differentiation and death occur sequentially, and each 
process is characterized by the expression of specific proteins 
including Filaggrin (FLG), Loricrin (LOR) and Involucrin (IVL) 
that are cross linked to form a impermeable skin barrier.
13
Profilaggrin is a member of the fused S100 family of S100 Ca
2+-
binding proteins and a large (-500 kDa) complex protein.
13,14 It 
is expressed in the granular layer of epidermis and consists of a 
unique N-terminal domain; a region with multiple FLG repeats; 
and a unique C-terminal end domain.
13,14 During terminal dif-
ferentiation at the granular to cornified cell transition, profilag-
grin is rapidly dephosphorylated and cleaved by several endo-
proteases including caspase-14, to generate FLG and the N-ter-
minal domain.
13,17,18 FLG aggregates the keratin filaments into 
tight bundles.
13,14 FLG proteolysis occurs upon exposure to a low 
humidity environment and might be inhibited by high humidi-
ty.
19 In the cornified cell, FLG is degraded into free amino acids 
by caspase-14 and these amino acids are essential for the reten-
tion of water contributing to the osmolarity in the cornified lay-
er.
17, 18 
LOR is expressed in the granular layer during cornification and 
an insoluble protein.
13,14 LOR is also one of the main components 
Review
Allergy Asthma Immunol Res. 2012 January;4(1):12-16.
http://dx.doi.org/10.4168/aair.2012.4.1.12
pISSN 2092-7355 • eISSN 2092-7363
Atopic dermatitis (AD) is a complex disease that affects up to 20% of children and impacts the quality of patients and families in a significant man-
ner. New insights into the pathophysiology of AD point to an important role of structural abnormalities in the epidermis combined with immune dys-
regulation. Filaggrin (FLG) is synthesized as a large precursor, profilaggrin, and is expressed in the upper layers of the epidermis. FLG plays a critical 
role in the epidermal barrier, and FLG mutations cause abnormal epidermal function. FLG mutations are strongly associated with early-onset, and 
persistent severe AD. In addition, FLG deficiency in the epidermis is related to allergic sensitization and asthma. The basic skin care including repair 
and protection of the skin barrier with proper hydration and topical anti-inflammatory therapy is important to control the severity of skin disease in 
patients with AD.
Key Words:  Atopic dermatitis; epidermal barrier; filaggrin
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to:  Donald YM Leung, MD, PhD, Department of Pediatrics, 
National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.
Tel: +1-303-398-1379; Fax: +1-303-270-2182; E-mail: leungd@njhealth.org
Received: July 27, 2011; Accepted: August 18, 2011
•There are no financial or other issues that might lead to conflict of interest.Epidermal Barrier in Atopic Dermatitis
Allergy Asthma Immunol Res. 2012 January;4(1):12-16.  http://dx.doi.org/10.4168/aair.2012.4.1.12
AAIR 
13 http://e-aair.org
of the epidermal envelope and is intermixed with profilaggrin, 
comprising 80% of the total protein mass of the cornified lay-
er.
20 LOR seems to function as a major reinforcement protein 
for the cornified envelope.
14,21 IVL is a common component of 
the cornified envelope and consists of repeating peptide units.
22 
IVL is an early component in the assembly of cornified envelops 
and provides a scaffold to which other proteins subsequently 
become crosslinked.
14 In the cornified-envelope structure, IVL 
is adjacent to the cell membrane.
14 
Roles of epidermal barrier
The epidermis serves as the first line of defense against invad-
ing pathogens and allergens.
3,23,24 The epidermal cornified layer 
is 15 to 29 nm thick and composed of structural proteins and a 
specialized lipid layer.
25,26 Various investigators have demon-
strated that a defective skin barrier enhances allergen sensitiza-
tion, leading to systemic allergic responses such as increased 
IgE levels and airway hyper-reactivity.
27,28 FLG deficiency alters 
the shape of corneocytes in the human skin,
12 and exhibits skin 
inflammation and enhances epicutaneous sensitization in mu-
rine models of eczema.
15 In addition, it has been shown that 
FLG deficiency confers a paracellular skin barrier abnormality 
that reduces inflammatory thresholds to irritants and haptens.
12
On the other hand, the absence of LOR in null mice results in 
no obvious abnormality, although an early, temporary deficien-
cy in water-barrier function is observed.
29 This indicates that 
keratinocytes could compensate for the loss of LOR by using 
other available proteins to form a functional cornified layer.
30 
The specialized lipid layer in the conrnified envelope also pro-
vide a barrier against water and prevent water loss.
11,12,26 
FLG mutations and AD
FLG mutations are the best known causes of impaired skin 
barrier and is considered as predisposing factors for AD.
2,31,32 
Many genes have been associated with AD and these genes in-
clude components of the epidermal skin barrier.
33 R510X and 
2282del4 are the most common mutant alleles associated with 
AD in Northern European populations with 10 to 50% of patients 
with AD having 1 of 2 loss-of-function mutations in FLG.
11,34-37 
The FLG mutations are currently considered as a major risk fac-
tor for AD, particularly in patients who have onset of AD at 2 
years or younger and patients with persistent AD.
31,38 It has been 
reported that an individual having one FLG null mutation is at 
four-fold greater risk of having early-onset AD, while an individ-
ual with two mutant FLG allels has an ~80-fold increased risk of 
developing AD compared with an individual with normal FLG 
alleles.
39 The FLG null alleles identified in asian populations are 
also significant predisposing factors for AD.
40,41
 However, it is likely that aside from FLG mutations, there will 
like be other causes of epidermal barrier defects in AD. In this 
regard, a significant number of patients with AD do not have 
any of the known FLG mutations, and conversely, approximate-
ly 40% of individuals with FLG-null alleles do not develop AD.
37 
In addition, up to 50% of patients with AD have FLG mutations, 
and those who have the mutation eventually recover from the 
disease.
42 Therefore, more work is needed to identify other 
causes of epidermal abnormalities in AD beyond FLG muta-
tions, and why some individuals never get AD despite the fact 
that they carry these mutations. 
Immune dysregulation of epidermal barrier in AD
The pathophysiology of AD is not well understood, although it 
Figure.  Filaggrin (FLG) expression and functions in the epidermal skin barrier. FLG is expressed in the granular layer of epidermis. Profilaggrin is dephosphorylated 
and cleaved by several endoproteases including caspase-14 to generate FLG, and then FLG is degraded into free amino acids (NMF) by caspase-14. 
Source: O’Regan et al. Journal of Allergy 
and Clinical Immunology 2009;124:R2-R6 
(DOI:10.1016/j.jaci.2009.07.013).
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is clear that gene-environment interactions in genetically pre-
disposed individuals play a central role. Investigators have 
shown a highly significant association between abnormalities 
in the epidermal barrier and risk of developing early-onset, se-
vere and persistent AD.
31,35,43 Of note, these may be due to both 
mutations of genes encoding proteins such as FLG, as well as 
modulation of epidermal protein levels by Th2 cytokines.
44,45 
The Th2 cytokines interleukin (IL)-4 and IL-13, which are over-
expressed in the acute skin lesions of AD patients, can down-
regulate FLG, LOR and IVL, potentially further exacerbating 
both the epidermal skin barrier defects.
44,45 A critical link between 
the barrier defect in AD patients with FLG mutations and Th2 
polarization could be explained in part by enhanced allergen 
penetration through the damaged epidermis accompanied by 
increased production of thymic stromal lymphopoietin (TSLP) 
by keratinocytes leading to a Th2-type milieu.
46 Importantly, 
patients with FLG gene mutations are at an increased risk for 
developing asthma, but only in the context of having AD, point-
ing to the importance of allergic sensitization through a dam-
aged skin barrier.
44,47,48 Conversely, AD patients with more polar-
ized Th2-type disease with allergies and asthma and increased 
biomarkers including serum IgE, TSLP and cutaneous T cell-at-
tracting chemokine were also more likely to have severe skin 
disease complicated by eczema herpeticum (EH), Staphylococ-
cus aureus or molluscum infections.
49 In addition, patients with 
FLG mutations have been found to have an increased risk for EH, 
a serious complication of AD.
46 Using a proteomics approach, 
Howell et al identified S100/A11 as a target in Th2 cytokine-me-
diated inhibition of FLG and the antimicrobial peptide, HBD-3, 
expression in AD skin, pointing to immune dysregulation ef-
fecting both epidermal barrier integrity and innate immune re-
sponse.
50 Still, the relationship of skin barrier and immune ab-
normalities to the increased susceptibility to microbial coloni-
zation and infections remains to be fully elucidated.
34 Of inter-
est, emerging observations that topical calcineurin inhibitors 
can in part correct the barrier defect in AD and that gentamicin 
can restore the production of functional FLG chains provides 
further evidence of the complex relationship of the epidermal 
barrier and the immune system.
51
Effects of topical therapy on skin barrier in AD
It has been shown that skin barrier function as assessed by 
transepidermal water loss (TEWL) is intrinsically compromised 
in children with AD, but not in children with other allergic con-
ditions.
52 In addition, TEWL was higher in white than in African 
American children with AD and the magnitude of skin barrier 
dysfunction correlated with disease severity.
52 While TEWL 
might be a useful biomarker in AD, racial and pigmentation dif-
ferences will need to be considered. Recently, authors examined 
TEWL and other parameters of epidermal barrier and showed 
improvement in all parameters when AD patients were treated 
with both a topical steroid (betamethazone valerate) and a top-
ical calcineurin inhibitor (pimecrolimus) applied to matched 
lesions.
53 Both treatments normalized epidermal differentiation 
and reduced epidermal hyperproliferation. Betamethazone 
valerate was better in reducing clinical symptoms and epider-
mal proliferation, however it induced epidermal thinning. In 
contrast, pimecrolimus did not cause skin atrophy. Therefore, 
we could conclude that pimecrolimus may be used for long-
term treatment, and betamethazone valerate might be more 
useful for treatment of acute exacerbations of AD.
54
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